Analysis of Novel Anticoagulants for Atrial Fibrillation – Pharmacokinetics and Pharmacological Considerations

References (43)

1. 1 Dabigatran versus Warfarin in Patients with Atrial Fibrillation [DOI]
2. 2 Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation [DOI]
3. 3 Apixaban versus Warfarin in Patients with Atrial Fibrillation [DOI]
4. 4 Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. [DOI]
5. 5 Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach [DOI]
6. 6 Prevalence of Diagnosed Atrial Fibrillation in Adults [DOI]
7. 7 Guidelines for the management of atrial fibrillation [DOI]
8. 8 Edoxaban versus Warfarin in Patients with Atrial Fibrillation [DOI]
9. 9 Validation of Clinical Classification Schemes for Predicting Stroke [DOI]
10. 10 Apixaban in Patients with Atrial Fibrillation [DOI]
11. 11 Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study [DOI]
12. 12 Systematic Overview of Warfarin and Its Drug and Food Interactions [DOI]
13. 13 Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review [DOI]
14. 14 The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects [DOI]
15. 15 The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans [DOI]
16. 16 Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate [DOI]
17. 17 In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor [DOI]
18. 18 Prevention of Atrial Fibrillation [DOI]
19. 19 Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation [DOI]
20. 20 Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation
21. 21 Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects [DOI]
22. 22 Use of the CHA 2 DS 2 -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation [DOI]
23. 23 Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation [DOI]
24. 24 How to Interpret and Pursue an Abnormal Prothrombin Time, Activated Partial Thromboplastin Time, and Bleeding Time in Adults [DOI]
25. 25 The new oral anticoagulants [DOI]
26. 26 Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays [DOI]
27. 27 Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation [DOI]
28. 28 In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban [DOI]
29. 29 Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [DOI]
30. 30 Newer oral anticoagulants: A review of laboratory monitoring options and reversal agents in the hemorrhagic patient [DOI]
31. 31 Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases [DOI]
32. 32 New oral anticoagulants in development [DOI]
33. 33 Rivaroxaban: An oral direct inhibitor of factor Xa [DOI]
34. 34 Dabigatran etexilate: A novel oral direct thrombin inhibitor [DOI]
35. 35 Apixaban in Patients with Atrial Fibrillation [DOI]
36. 36 Management of bleeding and reversal strategies for oral anticoagulants: Clinical practice considerations [DOI]
37. 37 Pharmacologic interventions for reversing the effects of oral anticoagulants [DOI]
38. 38 Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications [DOI]
39. 39 Oral anticoagulant therapies: Balancing the risks [DOI]
40. 40 Dabigatran Etexilate in Clinical Practice: Confronting Challenges to Improve Safety and Effectiveness [DOI]
41. 41 RIVAROXABAN - AN ORAL, DIRECT FACTOR XA INHIBITOR - BINDS RAPIDLY TO FACTOR XA [DOI]
42. 42 New oral therapies for the prevention and treatment of venous thromboembolism [DOI]
43. 43 Update on anti-coagulation in atrial fibrillation [DOI]

Cited by 0

No indexed citations yet.

Related research

• Thrombin Structural and Functional Determinants as Therapeutic Targets — shares topic coverage
• Thromboprophylaxis for Intensive Care Patients — shares topic coverage
• Expert Opinion on the Usage of Novel Oral Anticoagulants in Clinical Conditions in Indian Settings — shares topic coverage
• Secondary Thromboprophylaxis in Hereditary Thrombophilia — shares topic coverage
• A Tough Pill to Swallow- Spontaneous Retropharyngeal Hematoma: A Rare and Unusual Complication of Rivaroxaban Therapy — shares topic coverage